The bill introduced on March 20, 2025, aims to amend and update the Code of West Virginia regarding the classification of controlled substances. Key changes include the addition of new substances to Schedule I, such as Brorphine and a defined term for "fentanyl analog or derivative," while maintaining fentanyl and carfentanil as Schedule II substances. The bill also removes Norfentanyl from Schedule I and introduces new hallucinogenic substances, including PMMA. Furthermore, it expands the list of synthetic cannabinoids and opioids, ensuring that the classifications reflect current scientific understanding and public health concerns.

Additionally, the bill proposes several insertions and deletions to refine the language and substances listed in the schedules. Notable additions include gamma-hydroxybutyric acid (GHB) to the list of depressants, the replacement of "Declazepam" with "Diclazepam," and the introduction of new stimulants such as 4,4'-Dimethylaminorex and Ethylphenidate. Schedule IV will see the inclusion of new substances like Alfaxalone, Daridorexant, and Zuranolone, while Schedule V will add Ganaxolone. The overall goal of the bill is to enhance the regulatory framework surrounding controlled substances, ensuring it remains relevant and effective in addressing public health and safety concerns.

Statutes affected:
Introduced Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212